Meningococcal Acw & Y Vaccine Menactra Or Nimenrix
Menactra is a meningococcal conjugate vaccine to protect against meningococcal groups A, C, W and Y. Menactra is approved for use for those aged 9 months to 55 years.
From 1 December 2019, people aged 13-25 years living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons, can receive a single dose of meningococcal ACWY vaccine free of charge. The catch-up programme is only available until 30 November 2021. For more details see Section 13.5 of the Immunisation Handbook 2020.
The vaccine is funded for children and adults with a medical condition that increases their risk of invasive meningococcal disease AND is listed on the Pharmaceutical Schedule.
Menactra is also available as a purchased vaccine through your family doctor. The cost is approximately $150 per dose. For children aged 9 – 23 months, two doses are given at least three months apart. For individuals aged 2 – 55 years, one dose is given.
Meningococcal Vaccine: Canadian Immunization Guide
For health professionals
Latest partial content update :
: The chapter has been updated to align with the National Advisory Committee on Immunization Statement : The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B Vaccine for the Prevention of Meningococcal B Disease.
MenB-fHBP vaccine may be considered as an option for use in individuals 10 years of age and older in situations when a serogroup B meningococcal vaccine should be offered:
MenB-fHBP vaccine may be considered as an option for individuals 1025 years of age who are not at higher risk of meningococcal disease than the general population, but who wish to reduce their risk of invasive serogroup B meningococcal disease.
Last complete chapter revision: May 2015
Quadrivalent Meningococcal Conjugate Vaccine
Potential adverse reactions after meningococcal conjugate vaccines include localised pain, irritability, headache and fatigue. Fever is reported by 25 percent of adolescents who receive MenACWY-D.
The safety of two doses of MenACWY-D was assessed in a phase III trial of infants: dose one was administered at age 9 months and dose two was administered at age 12 months, with or without routine childhood vaccines. The percentage of participants with solicited systemic reactions after MenACWY-D administration alone at age 12 months was lower than after the vaccination at age 9 months , lower than the control groups at age 12 months and lower than when MenACWY-D was administered concurrently with the routine childhood vaccines .
The safety profile of MenACWY-T is very similar to other meningococcal conjugate vaccines.
There is no evidence of an association between meningococcal conjugate vaccines and GBS. An early report in the US of a suspected temporal association between MenACWY-D and GBS was followed by a large retrospective cohort study in the US that found no evidence of an increased risk of GBS following administration of MenACWY-D. If indicated, meningococcal conjugate vaccines may be administered to individuals with a history of GBS.
Don’t Miss: Is Mmr Vaccine For Meningitis
Who Should Get The Meningococcal Vaccine
- This vaccine is provided free to infants as part of their routine immunizations. The vaccine is given as a series of two doses. The first is given at 2 months of age, and the second at 12 months.
- This vaccine is also free for people:
- Born before 2002, who are 24 years of age and under who did not get a dose of vaccine on or after their 10th birthday.
- Who have been in close contact with someone with meningococcal type C disease.
Meningococcal Disease In Australia
Meningococcal disease can occur sporadically or in epidemics. In Australia, most cases occur during winter and early spring. Other countries with temperate climates also have this seasonal trend.95
The meningococcal serogroups that cause meningococcal disease have been changing. A meningococcal C vaccine was introduced on the National Immunisation Program in 2003 and has resulted in a large reduction in meningococcal C disease incidence.95,96
Meningococcal B has historically caused most meningococcal disease in Australia.96 Meningococcal B continues to cause around half of all reported cases of meningococcal disease in Australia.98
Meningococcal B is most common in South Australia, where a state-funded MenB vaccination program was introduced from 2018. Refer to the South Australian Health Department website for further details.
Because of substantial declines in invasive meningococcal disease caused by serogroups B and C, overall IMD incidence in Australia declined between 2003 and 2013.96
Since 2013, the incidence of meningococcal W disease has rapidly increased.98,99 Incidence of meningococcal Y disease has also been steadily increasing since 2016.98 Several states and territories implemented vaccination programs with MenACWY vaccine in 2017 to manage this disease. In 2018, MenACWY vaccine was introduced on the National Immunisation Program for toddlers aged 12 months. Adolescents are able to receive MenACWY vaccine on the National Immunisation Program from 2019.
Recommended Reading: How Many Vaccinated In Usa
Persons New To Canada
Health care providers who see persons newly arrived in Canada should review the immunization status and update immunization for these individuals. Review of meningococcal vaccination status is particularly important for persons from areas of the world where sickle cell disease is present as persons with sickle cell disease are at risk of serious meningococcal infections. In many countries outside of Canada, conjugate meningococcal vaccines are in limited use. Information on vaccination schedules in other countries can be found on the World Health Organization website. Refer to Immunization of Persons New to Canada in Part 3 for additional general information.
How Well It Works
The Men-C-C meningococcal vaccine works well. It protects about 97% of infants for one year after they get the vaccine and drops to 70% protection after one year. Booster shots of this vaccine are given to keep the protection level high. The Men-C-ACYW meningococcal vaccine works well and protects about 85% of people from meningococcal disease. The level of protection goes down over a period of years. Not enough information is available to say how long the 4CMenB vaccine protection lasts.
Recommended Reading: Is The Flu Shot A Vaccine
Why Do Teens Need A Meningococcal Vaccine
Of the 1,000-2,600 people who get meningococcal disease each year, one-third are teens and young adults. Ten percent to 15% of those who get sick with the disease will die, even with antibiotic treatment. As many as 20% of the survivorswill have permanent side effects, such as hearing loss or brain damage.
The immunization can help prevent this serious disease.
When Are Meningococcal Vaccines Given
Vaccination with MenACWY is recommended:
- when kids are 11 or 12 years old, with a booster given at age 16
- for teens 1318 years old who haven’t been vaccinated yet
Those who have their first dose between the ages of 1315 should get a booster dose between the ages of 1618. Teens who get their first dose after age 16 won’t need a booster dose.
Kids and teens who are at higher risk for meningococcal disease need the full series of MenACWY vaccines, even if they’re younger than 11 years old. This includes kids who:
- live in or travel to countries where the disease is common
- are present during an outbreak of the disease
- have some kinds of immune disorders. If the immune disorders are chronic, these kids also need a booster dose a few years later, depending on their age at the first dose.
The sequence and dosage depends on the child’s age, medical condition, and vaccine brand. Some types of meningococcal vaccines can be given as early as 8 weeks of age.
Kids 10 years and older with these risk factors also should get the MenB vaccine. They’ll need 2 or 3 doses depending on the brand. They might need more booster doses as long as the risk factor remains.
For those without risk factors, the decision to receive the MenB vaccine should be made together by teens, their parents, and the doctor. For them, the preferred age range is 1618 years. Usually, they need 2 doses.
Don’t Miss: What Is Zoster Vaccine Used For
Symptoms Of Meningococcal Disease
Neisseria meningitidis can cause invasive meningococcal disease , which usually presents as meningitis and septicaemia. Septicaemia, either on its own or with meningitis, can be particularly severe. N. meningitidis can also cause other localised infections, although these are less common, including:74,84
The clinical manifestations of meningococcal septicaemia and meningitis may be non-specific.
They can include:85
Not all symptoms or signs may be present at disease onset.
The characteristic rash of meningococcal disease does not disappear with gentle pressure on the skin, but the rash is not always present.
IMD can also present atypically as:
These atypical presentations are more common among certain serogroups, especially serogroup W.
What Is Meningococcal Disease
Meningococcal disease can refer to any illness caused by a type of bacteria called Neisseria meningitidis, also known as meningococcus . Meningococcal disease is not very common in the United States, but teens and young adults are at increased risk.
The two most common types of infections are
Also Check: What Vaccines Do Puppies Get At 8 Weeks
Types And Composition Of Meningococcal Vaccines
Of the 4 meningococcal vaccines available in the United States, 2 are conjugate vaccines and 2 are recombinant protein vaccines. Meningococcal vaccines also vary by the number of serogroups they provide protection against. Both recombinant protein vaccines are monovalent vaccines. This means the Food and Drug Administration licensed them to provide protection against 1 serogroup . In contrast, both conjugate vaccines provide protection against 4 serogroups , making them quadrivalent vaccines.
Who Should Not Get The Vaccine
Speak with your health care provider if you or your child have had a life-threatening reaction to a previous dose of any meningococcal vaccine, or any component of the vaccine.
There is no need to delay getting immunized because of a cold or other mild illness.
However, if you have concerns speak with your health care provider.
Also Check: Do I Need Meningitis Vaccine
What To Think About
The menigococcal vaccine can be given at the same time as other routine childhood vaccinations.
The conjugate meningococcal vaccines may be used during pregnancy when the benefits of getting the vaccine outweighs the risk.
The conjugate and multi-component vaccines may be given to women who are breastfeeding.
No evidence has shown that Canadian university students who live in dormitories or residence halls are at higher risk of getting meningococcal disease.footnote 2
When Should My Child Get The Vaccine
- Your child should be immunized with Men-C-C at 12 months of age. Your child may get earlier doses, started anytime between 2 and 12 months of age, depending on your province or territorys immunization program.
- Teens should get a dose of MCV-4 or Men-C-C, usually at about 12 years of age.
- Children at higher risk for meningococcal disease should receive MCV-4 and Men-B vaccine starting as early as 2 months of age. If you are unsure, talk to your doctor.
Also Check: Is Trumenba A Live Vaccine
Why Get Immunised Against Meningococcal Disease
Meningococcal disease is a very serious infection that can cause severe scarring, loss of limbs, brain damage and death.
Vaccination is a safe and effective way to protect yourself from meningococcal disease.
Meningococcal disease is most commonly caused by types A, B, C, W and Y. Vaccines can protect against all these types, but different vaccines protect against different types. No single vaccine protects against all types.
What Are The Risks From Meningococcal Vaccines
Most people have mild side effects from the vaccine, such as redness or pain where the shot was given. A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. This risk is extremely small. Getting the meningococcal vaccine is much safer than getting the disease.
You can learn more on the Vaccine Information Statements for meningococcal ACWY and meningococcal B.
Read Also: How Long Until Vaccine Works
Are Both Meningococcal Vaccines Equally Effective
The MCV4, MPSV4 and MenB vaccines are about 85-90% effective in preventing meningococcal disease. There are actually several types of N meningitidis — the bacterium that causes meningococcal disease, five of which are common in the U.S. These vaccines together protect against all five of these strains.
MCV4 has not been available long enough to compare the long-term effectiveness of the two vaccines. But most experts think that MCV4 provides better, longer-lasting protection.
Global Meningococcal Vaccines Market Is Projected To Reach At A Market Value Of Us$ 63475 Million By : Visiongain Research Inc
Visiongain has published a new report on Global Meningococcal Vaccines Market Report Forecast 2021-2031. Forecasts by Market Segment by Vaccine Type Market segment by End User and Market segment by Vaccine Brand . Plus, Profiles of Leading Meningococcal vaccine manufacturer Companies, Regional and Leading National Market Analysis. PLUS, COVID-19 Recovery Scenarios
Global Meningococcal Vaccines market was valued at US$ 3,560.9million in 2021 and is projected to reach at a market value of US$6,347.5million by 2031. Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from Non-profit Organizations is expected to drive the Global Meningococcal Vaccines Market. Strategizing Meningococcal Vaccine as a part of their National Immunization Programs by various countries has overall boosted the demand for meningococcal vaccines market
key Insight & Findings
COVID-19 Impact on Meningococcal Vaccines Market
What are the Market Drivers?
Increasing prevalence of meningitis
The growing occurrence of meningitis is one of the key factors likely to drive the market. As per the Centers for Disease Control and Prevention statistics, about 1.2 million cases of bacterial meningitis are anticipated to occur worldwide every year.
Increasing initiatives by government and regulatory authorities
Where are the Market Opportunities?
To access the data contained in this document please email
Recommended Reading: Why Does Everyone Need To Be Vaccinated
Can The Meningococcal Vaccine Cause Meningococcal Disease
The short answer is no. There are actually four meningococcal vaccines licensed in the U.S. None of the vaccines contains live bacteria.
The vaccines contain antigens — substances that trigger the body’s immune system and cause it to make antibodies. These antibodies then protect the body by attacking and killing the bacteria if it should invade your system.
The first vaccine — meningococcal polysaccharide vaccine or MPSV4 — was approved in 1978. It’s made with the antigens contained in the outer polysaccharide or sugar capsule that surrounds the bacterium.
The meningococcal conjugate vaccine or MCV4 was approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body’s immune cells. This makes it easier for the body’s immune system to see and recognize the antigens.
One type of MCV4, Menveo, is licensed for use in people ages 2 to 55. Another version, Menactra, is approved for those 9 months to 55 years old. MPSV4 is the only vaccine licensed for use in people over 55 as well as people 2 to 55. Both vaccines protect against four types of meningococcal disease.
Who Should Get The Meningococcal Vaccines
The MenACWY vaccine is recommended for college freshman living in a dormitory. The vaccine has been recommended for 11-12 year olds since 2005, so it is possible that incoming freshmen have already received a dose. If you received a dose before age 16, you should get a booster before you go to college.
Don’t Miss: Does Cvs Offer Tdap Vaccine
Where And When Can I Get The Vaccine
Talk to your doctor or local public health clinic to find out where and when your child should get vaccinated.
- The cost of Men-C-C is covered everywhere in Canada.
- Many provinces currently cover the cost of MCV-4 vaccine.
- Currently, no provinces or territories cover the cost of Men-B vaccine for all children. Some provide it for children at high risk of getting meningococcal disease.
Where Can I Get Vaccinated
The best place to go for vaccinations is your family medical clinic. They have your medical records and can check to see if youve already had a particular vaccination. Either your doctor or a nurse can give the vaccination. If you dont have a family doctor , you can go to one of the after-hour medical clinics. phone them first to make sure they can help you with the vaccination you need. You can find a clinic near you on the Healthpoint website. Put in your address and region, and under Select a service, click on GPs/Accident & Urgent Medical Care.Vaccines on the National Immunisation Schedule are free. Other vaccines are funded only for people at particular risk of disease. You can choose to pay for vaccines that you are not eligible to receive for free.
Don’t Miss: Does Walgreens Have Meningitis Vaccine
How Is Meningococcal Disease Spread And Who Is Most At Risk
Meningococcal disease is not as contagious as other illnesses, such as a cold or the flu. But it is spread by contact with infected respiratory and throat secretions. That can happen with coughing, kissing, or sneezing.
Because the risk increases with close or prolonged contact with an infected person, family members in the same household and caregivers are at an increased risk. For the same reason, so are college students who live in dormitories.
How Do You Get Immunised Against Meningococcal Disease
You can get meningococcal vaccines on their own or as a combination vaccine. Different vaccines protect against different types of meningococcal disease. They are all given as a needle.
Meningococcal vaccines include:
Your doctor can tell you which vaccine they will use for your meningococcal immunisation.
You May Like: What Vaccines Do 11 Year Olds Get